130 related articles for article (PubMed ID: 28725874)
1. Metabolites of alectinib in human: their identification and pharmacological activity.
Sato-Nakai M; Kawashima K; Nakagawa T; Tachibana Y; Yoshida M; Takanashi K; Morcos PN; Binder M; Moore DJ; Yu L
Heliyon; 2017 Jul; 3(7):e00354. PubMed ID: 28725874
[TBL] [Abstract][Full Text] [Related]
2. In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes.
Nakagawa T; Fowler S; Takanashi K; Youdim K; Yamauchi T; Kawashima K; Sato-Nakai M; Yu L; Ishigai M
Xenobiotica; 2018 Jun; 48(6):546-554. PubMed ID: 28657423
[TBL] [Abstract][Full Text] [Related]
3. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
Morcos PN; Yu L; Bogman K; Sato M; Katsuki H; Kawashima K; Moore DJ; Whayman M; Nieforth K; Heinig K; Guerini E; Muri D; Martin-Facklam M; Phipps A
Xenobiotica; 2017 Mar; 47(3):217-229. PubMed ID: 27180975
[TBL] [Abstract][Full Text] [Related]
4. Metabolic study of androsta-1,4,6-triene-3,17-dione in horses using liquid chromatography/high resolution mass spectrometry.
Kwok WH; Leung GN; Wan TS; Curl P; Schiff PJ
J Steroid Biochem Mol Biol; 2015 Aug; 152():142-54. PubMed ID: 26031748
[TBL] [Abstract][Full Text] [Related]
5. Metabolic study of methylstenbolone in horses using liquid chromatography-high resolution mass spectrometry and gas chromatography-mass spectrometry.
Choi TLS; Wong JKY; Kwok WH; Curl P; Mechie S; Wan TSM
J Chromatogr A; 2018 Apr; 1546():106-118. PubMed ID: 29548567
[TBL] [Abstract][Full Text] [Related]
6. Metabolic studies of oxyguno in horses.
Wong AS; Ho EN; Wan TS; Lam KK; Stewart BD
Anal Chim Acta; 2015 Sep; 891():190-202. PubMed ID: 26388378
[TBL] [Abstract][Full Text] [Related]
7. LC-MS/MS determination of alectinib and its major human metabolite M4 in human urine: prevention of nonspecific binding.
Heinig K; Herzog D; Ferrari L; Fraier D; Miya K; Morcos PN
Bioanalysis; 2017 Mar; 9(5):459-468. PubMed ID: 28176528
[TBL] [Abstract][Full Text] [Related]
8. Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.
Morcos PN; Guerini E; Parrott N; Dall G; Blotner S; Bogman K; Sturm C; Balas B; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):388-397. PubMed ID: 27545320
[TBL] [Abstract][Full Text] [Related]
9. Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib.
Morcos PN; Cleary Y; Sturm-Pellanda C; Guerini E; Abt M; Donzelli M; Vazvaei F; Balas B; Parrott N; Yu L
J Clin Pharmacol; 2018 Dec; 58(12):1618-1628. PubMed ID: 30052269
[TBL] [Abstract][Full Text] [Related]
10. Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
Morcos PN; Cleary Y; Guerini E; Dall G; Bogman K; De Petris L; Viteri S; Bordogna W; Yu L; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 May; 6(3):280-291. PubMed ID: 27545757
[TBL] [Abstract][Full Text] [Related]
11. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
Prakash C; O'Donnell J; Khojasteh-Bakht SC
Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
[TBL] [Abstract][Full Text] [Related]
12. Bioanalysis of alectinib and metabolite M4 in human plasma, cross-validation and impact on PK assessment.
Heinig K; Miya K; Kamei T; Guerini E; Fraier D; Yu L; Bansal S; Morcos PN
Bioanalysis; 2016 Jul; 8(14):1465-79. PubMed ID: 27329641
[TBL] [Abstract][Full Text] [Related]
13. Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects.
Morcos PN; Parrott N; Banken L; Timpe C; Lindenberg M; Guerini E; Dall G; Bogman K; Sturm C; Zeaiter A; Martin-Facklam M; Phipps A
Clin Pharmacol Drug Dev; 2017 May; 6(3):266-279. PubMed ID: 27545871
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective ALK inhibitor, alectinib.
Sekiguchi N; Nagao S; Takanashi K; Kato M; Kaneko A; Morita K; Shindoh H; Ishigai M
Xenobiotica; 2017 Dec; 47(12):1042-1051. PubMed ID: 27841077
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor.
Zhang D; Hanson R; Roongta V; Dischino DD; Gao Q; Sloan CP; Polson C; Keavy D; Zheng M; Mitroka J; Yeola S
Curr Drug Metab; 2006 Dec; 7(8):883-96. PubMed ID: 17168689
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.
Tiseo PJ; Perdomo CA; Friedhoff LT
Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):19-24. PubMed ID: 9839761
[TBL] [Abstract][Full Text] [Related]
17. Biotransformation of the xanthine oxidase inhibitor BOF-4272 and its metabolites in the liver and by the intestinal flora in rat.
Naito S; Nishimura M
Xenobiotica; 2000 Jan; 30(1):103-9. PubMed ID: 10659955
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
Lee SS; Kim SB; Park SI; Kim YH; Ryu JS; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Jpn J Clin Oncol; 2007 Nov; 37(11):829-35. PubMed ID: 17951334
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats.
Murai T; Takakusa H; Nakai D; Kamiyama E; Taira T; Kimura T; Jimbo T; Bathala M; Pickersgill F; Zahir H; Tokui T; Savage RE; Ashwell MA; Izumi T
Xenobiotica; 2014 Nov; 44(11):996-1008. PubMed ID: 24911380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
